TScan Therapeutics, Inc. (TCRX) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 49 transactions totaling $27.9M, demonstrating a bullish sentiment with $25.8M in net insider flow. The most recent transaction on Jan 20, 2026 involved a transaction of 1,165,000 shares valued at $0.
No significant insider buying has been recorded for TCRX in the recent period.
No significant insider selling has been recorded for TCRX in the recent period.
Based on recent SEC filings, insider sentiment for TCRX is bullish with an Insider Alignment Score of 96/100 and a net flow of $25.8M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at TScan Therapeutics, Inc. (TCRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading TCRX stock, having executed 49 transactions in the past 90 days. The most active insider is L.p. 667, (Executive), who has made 10 transactions totaling $23.9M.
Get notified when executives and directors at TCRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Macbeath Gavin | Executive | Award | 1,165,000 | $N/A | $0 | |
| Jan 20, 2026 | Amello Jason | Chief Financial Officer | Award | 350,000 | $N/A | $0 | C-Suite |
| Jan 20, 2026 | Louis Chrystal | Chief Medical Officer | Award | 420,000 | $N/A | $0 | |
| Jan 20, 2026 | Dworak Leiden | See Remarks | Award | 100,000 | $N/A | $0 | |
| Dec 23, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 6,232 | $0.90 | $5.6K | |
| Dec 22, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 75,500 | $0.90 | $68.0K | |
| Dec 19, 2025 | Management Lp Lynx1 Capital | Executive | Purchase | 80,069 | $0.90 | $72.1K | |
| Sep 23, 2024 | Klencke Barbara | Executive | Purchase | 5,000 | $5.29 | $26.4K | |
| Aug 26, 2024 | Klencke Barbara | Executive | Purchase | 5,000 | $5.53 | $27.6K | |
| Aug 23, 2024 | Zdraveski Zoran | Executive | Option Exercise | 54,895 | $4.85 | $266.2K | |
| Aug 23, 2024 | Zdraveski Zoran | Executive | Option Exercise | 25,000 | $3.27 | $81.8K | |
| Aug 23, 2024 | Zdraveski Zoran | Executive | Option Exercise | 13,125 | $1.81 | $23.8K | |
| Aug 23, 2024 | Zdraveski Zoran | Executive | Option Exercise | 64,166 | $2.49 | $159.8K | |
| Aug 23, 2024 | Zdraveski Zoran | Executive | Sale | 164,686 | $5.78 | $951.9K | Large |
| Aug 23, 2024 | Klencke Barbara | Executive | Purchase | 5,000 | $5.69 | $28.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 34 | $26.9M | 94.2% |
Sale(S) | 4 | $1.0M | 3.6% |
Exercise(M) | 5 | $627.4K | 2.2% |
Award(A) | 4 | $0 | 0.0% |
Conversion(C) | 2 | $0 | 0.0% |
Insiders at TScan Therapeutics, Inc. are accumulating shares at an accelerated pace. With 13 insiders making 49 transactions totaling $26.9M in purchases versus $1.0M in sales, the net buying activity of $25.8M signals strong executive confidence. L.p. 667, (Executive) leads the buying activity with $23.9M in transactions across all time.